High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors
Protein & Cell
;
(12): 877-888, 2021.
Article
Dans Anglais
| WPRIM
| ID: wpr-922482
ABSTRACT
A new coronavirus (SARS-CoV-2) has been identified as the etiologic agent for the COVID-19 outbreak. Currently, effective treatment options remain very limited for this disease; therefore, there is an urgent need to identify new anti-COVID-19 agents. In this study, we screened over 6,000 compounds that included approved drugs, drug candidates in clinical trials, and pharmacologically active compounds to identify leads that target the SARS-CoV-2 papain-like protease (PLpro). Together with main protease (M
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Antiviraux
/
Inhibiteurs de protéases
/
Sites de fixation
/
Protéines recombinantes
/
Mutagenèse dirigée
/
Naphtoquinones
/
Structure tertiaire des protéines
/
Cristallographie aux rayons X
/
Concentration inhibitrice 50
/
Évaluation préclinique de médicament
Type d'étude:
Etude diagnostique
/
Étude de dépistage
Limites du sujet:
Humains
langue:
Anglais
Texte intégral:
Protein & Cell
Année:
2021
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS